BioCryst Pharmaceuticals (BCRX) Posts Wider than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.14 +1.67%
Revenue Growth %: +13.7%
Financial Fact:
Product sales: 0
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +13.7%
Financial Fact:
Product sales: 0
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioCryst Pharmaceuticals (Nasdaq: BCRX) reported Q1 loss of ($0.29), $0.09 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $17.04 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- PowerFleet, Inc. (AIOT) Misses Q1 EPS by 2c ; Offers Guidance
- John Wiley & Sons, Inc. (WLYB) Tops Q4 EPS by 12c; Offers Outlook
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
